Mixed cryoglobulinemic vasculitis is associated with monoclonal B cell expansion in patients with chronic hepatitis C (HCV) infection. B cell depletion therapy using rituximab, a CD20 monoclonal antibody, has been successful in achieving remission from symptomatic disease. This study investigated whether B cell depletion therapy has an impact on activation of HCV-specific T cell phenotype and function. Nineteen CD4+ (16.9 ± 0.9% to 8.9 ± 1.0%) and CD8+ (6.8 ± 0.6% to 3.0 ± 0.5%) T cells expressing PD-1 and CD4+ (11.0 ± 1.0% to 6.1 ± 0.8%) and CD8+ (12.7 ± 0.7% to 6.4 ± 0.4%) T cells expressing TIM-3. In addition, there was a significantly higher percentage of peripheral CD8+ T cells responding to HCV peptide stimulation in vitro secreting IFN-γ (4.55 ± 0.3 to 9.6 ± 1.0 IFN-γ/10 6 PBMCs, P < 0.0001), and more than one cytokine (1.3 ± 0.1% to 3.8 ± 0.2%, P < 0.0001) after therapy compared to pretherapy. B cell depletion therapy results in recovery of T cell exhaustion and function in patients with HCV cryoglobulinemic vasculitis.
thyroiditis, hypothyroidism, papillary thyroid cancer, and type 2 diabetes mellitus. 6, 8 While most EHM are provisionally associated with chronic HCV infection, 9 Type II MC vasculitis is perhaps the most strongly associated with HCV, [7] [8] [9] [10] [11] as 70-86% of symptomatic patients have HCV viremia. [12] [13] [14] Pathogenesis of HCV-associated MC vasculitis is categorized by preferential expansion of monoclonal B cells, 15 probably triggered by HCV neoantigens/epitopes, which produce soluble IgM with rheumatoid factor activity capable of forming immune complexes that fix complement, resulting in glomerulonephritis, and small vessel vasculitis. 6, 9, 13 Clinical signs of HCV-associated MC vasculitis include classic manifestations of systemic immune complex diseases, such as cutaneous vasculitis (non-healing ulcers), arthralgia/arthritis, peripheral neuropathy, and membranoproliferative glomerulonephritis. [16] [17] [18] The pathogenesis of immunological abnormalities associated with HCV-MC vasculitis, the nature of HCV infection leading to MC vasculitis, and the role of B cells are not completely understood. Recent clinical trials have shown HCV-MC vasculitis patients can be effectively treated with rituximab, an anti-CD20 monoclonal antibody, resulting in symptomatic relief. 10, 11, 19, 20 Rituximab is known to normalize peripheral B-and T-lymphocyte homeostasis by improving regulation, activation, Th1/Th2 imbalances, 21 and increasing CD4+ T cells. 11 However, it is unclear how resetting of B cell homeostasis using In the present study, we sought to further characterize T cell phenotype and function, and reversal of T cell exhaustion, with respect to HCV specificity before and after rituximab therapy in patients with HCV-MC. 
| MATERIALS AND METHODS

| Study population
| IFN-γ ELISPOT to characterize HCV-specific T cell responses
To quantified by standard ELISPOT assay (BD Biosciences, San Jose, CA).
In summary, 96 well ELISPOT plates were coated with anti-IFN-γ biotinylated capture antibody and incubated overnight at 4°C. Plates were then blocked using lymphocyte medium, and PBMCs were allowed to rest for 6 h at 37°C. PBMCs were plated between 250 000-400 000 cells per well with either phytohemagglutin as a positive control (5 μg/mL), dimethyl sulfoxide as a negative control (0.05%), or pooled HCV peptides (3 μg/mL). All cultures were performed in duplicate. After incubating for 12 h at 37°C, cells were removed, and plated with streptavidin detection antibody, enzyme conjugate, and substrate. The plates were air dried in the dark overnight, and developed spots were enumerated using an ELISPOT plate reader. The frequency of IFN-γ-producing cells was calculated as described previously. phenotype, and function using the antibodies described previously.
The gating strategy is shown in supplementary Figure S1 .
To assess secreted cytokine production, 100 μL of supernatant from cultured PBMC was collected at 36 h and frozen at −80°C until used. Samples were thawed and analyzed for cytoking production using Mesoscale Discovery Human TH1/TH2 10-plex ultra-sensitive kit (catalog K#15010C-1), according to the manufacturer's protocol.
All samples were tested in duplicate.
| Statistical analysis
The primary analysis assessed the individual differences between CD4
+ and CD8+ T cell expressing exhaustive phenotype and secreting one or more cytokines after stimulation with HCV peptides from pretherapy to post-therapy (6 months after starting rituximab therapy) using a paired t-test. We also explored if there was a difference in the change of these parameters between patients who received immediate versus delayed therapy. All analysis was conducted in GraphPad
Prism 5 with a P-value <0.05 (two-sided) indicating statistical significance.
3 | RESULTS
| Study population
The clinical and demographic characteristics of patients from the clinical trial, and that rituximab therapy was successful with a clinical response, have been previously described. 10 The rituximab and control group (immediate and delayed therapy) were balanced in demographics, clinical manifestations, disease activity, laboratory values, and exposure to glucocorticoids and other immunosuppressive therapies. 
| Decline in CD4 and CD8+ T cells with exhaustive phenotype after B cell depletion therapy
Collectively, CD4+ and CD8+ T cells from all patients experienced a decline in PD-1 and TIM-3 expression with rituximab therapy. Overall, there was a significant decline in change from pre-therapy to posttherapy in CD4+ T cells expressing both PD-1 (pre-therapy 16.9 ± 0.9% and post-therapy 8.9 ± 1.0%, P < 0.0001) and TIM-3 (pre-therapy 11.0 ± 1.0% and post-therapy 6.1 ± 0.8%, P < 0.0001) (Figures 1 and 2 ). There was no difference in the change between patients who received immediate rituximab compared to those who received delayed therapy.
Overall, there was a significant decline in change from pre-therapy to post-therapy in CD8+ T cells expressing both PD-1 (pre-therapy 6.8 ± 0.6% and post-therapy 3.0 ± 0.5%, P < 0.0001) and TIM-3 (pre-therapy 12.7 ± 0.7% and post-therapy 6.4 ± 0.4%, P < 0.0001) (Figures 1 and 2 ). There was no difference in the change between 
| Enhancement of CD8+ T cells secreting multiple cytokines in response to HCV peptide stimulation with B cell depletion therapy
There was a significant increase in polyfunctionality (more than one cytokine) from pre-therapy (1.3 ± 0.1%) to post-therapy (3.8 ± 0.2%), 
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